Medical management of melanoma (Q35126548)

6 August 2017

1 reference

title

Medical management of melanoma (English)

1 reference

6 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

2 January 2024

author name string

Charles Komen Brown

1

1 reference

6 August 2017

John M. Kirkwood

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12744611

2 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12744611

2 January 2024

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0039610902001871?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

https://api.elsevier.com/content/article/PII:S0039610902001871?httpAccept=text/plain

2 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Surgical Clinics of North America

2 January 2024

published in

1 reference

6 August 2017

83

1 reference

6 August 2017

2

1 reference

6 August 2017

283-322, viii

1 reference

Virus interference. I. The interferon

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Therapy of chronic myelogenous leukemia with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Human T-lymphocyte subset production of immune (?) interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Response of resting human peripheral blood natural killer cells to interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant immunotherapy with BCG in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Active immunotherapy with B.C.G. for recurrent malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Intralesional BCG in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Mechanisms of macrophage activation by Corynebacterium parvum. I. In vitro experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Controlled trial of active immunotherapy in management of stage IIB malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Immunotherapy of human cancer: lessons from mice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant Treatment in Stage I and II Malignant Melanoma: A Randomized Trial between Chemoimmunotherapy and Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Adjuvant chemoimmunotherapy stage I/II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interferons in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interferons in the therapy of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Immunotherapy and experimental approaches for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Vitiligo in patients with metastatic melanoma: a good prognostic sign

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Accumulation of identical T cells in melanoma and vitiligo-like leukoderma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

The immune response in halo nevi

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Active specific immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Active-specific immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Results with methyl-CCNU and DTIC in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase II trial of carboplatin in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Combination chemotherapy for disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

A phase II trial of zeniplatin in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900187-1

7 January 2021

Recent advances in the therapy of chronic myelogenous leukemia

14

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Human interferons: structure and function

2 January 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Melanoma: therapeutic options with recombinant interferons

2 January 2024

20

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer

2 January 2024

31

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages

2 January 2024

35

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Adjuvant BCG immunotherapy for malignant melanoma

2 January 2024

45

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Adjuvant BCG immunotherapy for stage I and II malignant melanoma

2 January 2024

46

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside

2 January 2024

65

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

DTIC (NSC-45388) in malignant melanoma: a perspective

2 January 2024

68

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases

2 January 2024

84

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma

2 January 2024

85

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

2 January 2024

105

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A

2 January 2024

113

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Chemotherapy for metastatic melanoma

2 January 2024

129

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Eastern Cooperative Oncology Group studies with DTIC (NSC-45388)

2 January 2024

130

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma

2 January 2024

148

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma

2 January 2024

152

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma

2 January 2024

154

1 reference

https://api.crossref.org/works/10.1016/S0039-6109(02)00187-1

2 January 2024

Identifiers

1 reference

release_6d2x4p5uvvh2tkpauonmrg7l7u

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6d2x4p5uvvh2tkpauonmrg7l7u

24 November 2022

mapped directly with Wikidata item

1 reference